Randomized comparison of everolimus-eluting and paclitaxel-eluting stents: pooled analysis of 3-year clinical outcomes from the Spirit II and III Trials

Alexandra J. Lansky; James Hermiller; Robert J. Applegate; Adriano Caixeta; Paul Gordon; Peter Ruygrok; Julie Doostzadeh; Karine Miquel‐Hébert; Susan Veldhof; Poornima Sood; Xiaolu Su; Krishnankutty Sudhir; Patrick W. Serruys; Gregg W. Stone

doi:10.1016/j.carrev.2010.03.028

Related publications

Article2011

EVEROLIMUS-ELUTING VS. PACLITAXEL-ELUTING STENTS. TWO-YEAR RESULTS FROM A PATIENT-LEVEL POOLED ANALYSIS FROM THE SPIRIT II, III, IV AND COMPARE RANDOMIZED TRIALS

Elvin Kedhi, Pieter C. Smits, Patrick W. Serruys, Dean J. Kereiakes, Helen Parise, Martin Fahy, Gregg W. Stone

Journal of the American College of Cardiology

Article2011

STENT THROMBOSIS AFTER EVEROLIMUS-ELUTING VERSUS PACLITAXEL-ELUTING CORONARY STENTS: INSIGHTS FROM THE SPIRIT II, SPIRIT III, SPIRIT IV AND COMPARE POOLED DATABASE

Pieter C. Smits, Elvin Kedhi, Dean J. Kereiakes, Patrick W. Serruys, Helen Parise, Martin Fahy, Gregg W. Stone, Maasstad Ziekenhuis

Journal of the American College of Cardiology

Article2011

COMPARISON OF THE EVEROLIMUS-ELUTING AND PACLITAXEL-ELUTING STENTS IN PATIENTS WITH ACUTE AND STABLE CORONARY SYNDROMES. RESULTS FROM THE SPIRIT II, III, IV AND COMPARE TRIALS

David Planer, Pieter C. Smits, Dean J. Kereiakes, Elvin Kedhi, Martin Fahy, Patrick W. Serruys, Gregg W. Stone

Journal of the American College of Cardiology

Article2010

Abstract 17174: Predictors of Stent Thrombosis after Everolimus-Eluting and Paclitaxel-Eluting Stents: The Pooled SPIRIT Randomized Trial Experience at Two Years of Follow-Up

Ajay J. Kirtane, Poornima Sood, Robert J. Applegate, Manejeh Yaqub, Yoshinobu Onuma, John C. Wang, Xiaolu Su, Karine Miquel‐Hébert, Alexandra J. Lansky, Dean J. Kereiakes, Charles A. Simonton, Krishnankutty Sudhir, Patrick W. Serruys, Gregg W. Stone

Circulation

Article2020

Bioresorbable scaffolds versus everolimus-eluting metallic stents: five-year clinical outcomes of the randomised ABSORB II trial

Yoshinobu Onuma, Bernard Chevalier, Masafumi Ono, Ángel Cequier, Dariusz Dudek, Michael Haude, Didier Carrié, Manel Sabaté, Stephan Windecker, Richard Rapoza, Nick E.J. West, Sebastian Reith, Manuel de Sousa Almeida, Gianluca Campo, Andrés Íñiguez, Patrick W. Serruys

EuroIntervention

Randomized comparison of everolimus-eluting and paclitaxel-eluting stents: pooled analysis of 3-year clinical outcomes from the Spirit II and III Trials

Abstract

Discussion(0)

Related publications

EVEROLIMUS-ELUTING VS. PACLITAXEL-ELUTING STENTS. TWO-YEAR RESULTS FROM A PATIENT-LEVEL POOLED ANALYSIS FROM THE SPIRIT II, III, IV AND COMPARE RANDOMIZED TRIALS

STENT THROMBOSIS AFTER EVEROLIMUS-ELUTING VERSUS PACLITAXEL-ELUTING CORONARY STENTS: INSIGHTS FROM THE SPIRIT II, SPIRIT III, SPIRIT IV AND COMPARE POOLED DATABASE

COMPARISON OF THE EVEROLIMUS-ELUTING AND PACLITAXEL-ELUTING STENTS IN PATIENTS WITH ACUTE AND STABLE CORONARY SYNDROMES. RESULTS FROM THE SPIRIT II, III, IV AND COMPARE TRIALS

Abstract 17174: Predictors of Stent Thrombosis after Everolimus-Eluting and Paclitaxel-Eluting Stents: The Pooled SPIRIT Randomized Trial Experience at Two Years of Follow-Up

Bioresorbable scaffolds versus everolimus-eluting metallic stents: five-year clinical outcomes of the randomised ABSORB II trial